Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of LXS196 alone or with HDM201 in metastatic uveal melanoma
NL-OMON47593Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of darovasertib and siremadlin in intraocular melanoma (2 arms), sponsored by Novartis. Primary endpoint: Safety and tolerability. Started Jan 2016; status: active, not recruiting.
02
Drugs
darovasertibsiremadlin
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on NL-OMON47593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47593.